Centella Asiatica & Wound Healing Botanicals: Madecassoside vs Asiaticoside Data

Overview #

Centella asiatica sits at the intersection of traditional wound-healing medicine and modern barrier-repair science — and for good reason. The challenge for brand partners isn’t whether to use it, but which fraction to use, at what concentration, and in what delivery system. Brands building sensitive-skin, post-procedure, or barrier-repair lines benefit most from understanding the difference between standardized extracts, isolated madecassoside, and asiaticoside-dominant fractions. The short answer: if your claim is “calming,” a standardized total triterpene extract at 1–2% usually gets you there. If your claim is “wound healing” or “post-laser recovery,” you need isolated madecassoside at ≥0.1%, and the formulation strategy changes significantly.

Madecassoside vs Asiaticoside: What the Data Actually Shows #

Most suppliers pitch Centella extracts as interchangeable. They’re not. The two primary bioactive triterpenes — madecassoside and asiaticoside — have meaningfully different mechanisms, and conflating them is one of the most common brief mistakes we see from brand partners.

Madecassoside is the collagen-stimulating fraction. In our formulation lab, we’ve run side-by-side stability and efficacy comparisons across multiple projects, and the clinical literature backs what we observe internally. A 2019 double-blind, split-face RCT (n=44, 8 weeks, published in Journal of Cosmetic Dermatology) showed that a 0.1% madecassoside serum produced a 34% reduction in transepidermal water loss (TEWL) and a 28% improvement in skin barrier integrity scores versus vehicle control. Asiaticoside at equivalent concentration showed roughly half the TEWL improvement in the same study design. That gap matters when you’re writing clinical claims.

Asiaticoside, on the other hand, is the anti-inflammatory and wound-contraction driver. It upregulates TGF-β1 signaling and promotes fibroblast proliferation — which is why it’s historically been used in pharmaceutical scar treatment formulations. The problem is that asiaticoside is also the fraction most likely to cause sensitization at higher concentrations. We’ve seen this in our own patch testing: above 0.5% isolated asiaticoside, we start seeing borderline reactions in our in-house repeat insult patch test (RIPT) panels. Most brands don’t know this threshold exists.

Asiatic acid and madecassic acid — the aglycone forms — are more lipophilic and penetrate faster, but they’re also harder to stabilize in aqueous systems. Drop below pH 5.0 and you accelerate hydrolysis of the glycoside bonds. We stabilize our Centella actives at pH 5.2–5.8 using a citrate buffer system, and we still see measurable degradation in clear gel formats after 12 weeks at 40°C if the antioxidant package isn’t right.

Centella Fraction Comparison: Performance, Stability & Application #

Honestly, most brands underestimate the difference between the last row and everything above it. Non-standardized leaf extract can have triterpene content ranging from 0.1% to over 3% depending on harvest season, geography, and extraction method. We’ve received supplier batches that tested at less than 20% of the declared active content. That’s not a formulation problem — that’s a sourcing problem that becomes your formulation problem.

Formulation Strategy: Delivery Systems and Compatibility #

Getting the right Centella fraction is step one. Getting it into a stable, skin-compatible delivery system is where most projects actually succeed or fail.

For madecassoside-dominant formulations, we work primarily in oil-in-water emulsions at pH 5.2–5.6. The molecule is water-soluble, so it goes into the aqueous phase — but the aqueous phase needs to be protected. We use a combination of 0.5% sodium ascorbyl phosphate as a co-antioxidant and keep the preservative system away from formaldehyde-releasing agents, which we’ve found accelerate triterpene degradation in accelerated stability testing. At 40°C/75% RH over 8 weeks, a well-formulated madecassoside serum should hold above 90% active content. If it drops below 85%, we reformulate before moving to pilot scale.

Encapsulation is worth discussing here. For brands targeting post-procedure or medical-adjacent positioning, we’ve had good results with liposomal encapsulation of the total triterpene fraction — our encapsulation technology platform can achieve encapsulation efficiency above 78% for TECA fractions, which meaningfully extends shelf stability and improves dermal delivery in our in-vitro Franz cell diffusion models. The tradeoff is cost: encapsulated Centella adds roughly 15–25% to raw material cost per kg of finished formula, and not every brand brief justifies it.

One failure mode we’ve hit more than once: combining high-concentration Centella extract with niacinamide above 4% in the same aqueous phase. We observed a yellowing reaction in three separate pilot batches — not catastrophic, but enough to fail consumer acceptance testing. The mechanism isn’t fully understood, even internally. We now flag this combination in every kickoff call and either separate the phases or reduce niacinamide to ≤2% when Centella is the hero active.

For barrier-repair and sensitive-skin formulations, the texture system matters as much as the active. We’ve found that Centella actives perform better in ceramide-rich emulsion bases than in simple humectant gels — the lipid matrix appears to support the barrier-repair mechanism rather than just delivering the active to the surface. This is observational from our internal projects, not a controlled study, but it’s consistent enough that we now recommend it as a default.

Regulatory positioning varies by market. Under the EU Cosmetics Regulation 1223/2009, Centella asiatica and its isolated fractions are classified as cosmetic ingredients with no current concentration restrictions — but claims touching on “wound healing” or “tissue repair” can push a product toward medicinal classification under Directive 2001/83/EC. We’ve had EU brand partners come to us with “wound healing serum” briefs that we had to reframe as “skin recovery” to stay in cosmetic territory. The SCCS Scientific Opinion on botanical actives is worth reviewing if you’re building claims for the EU market. For the US market, FDA Cosmetics Guidelines apply the same OTC drug boundary — “wound healing” as a label claim triggers drug classification regardless of the ingredient.

Sourcing, Standardization, and What We Ask Suppliers #

This is usually where projects go sideways. The Centella supply chain is fragmented, and “standardized extract” means different things from different suppliers.

When we qualify a new Centella supplier, we require HPLC certificates of analysis showing individual triterpene content — not just “total triterpenes.” We’ve seen suppliers report 40% TECA (total extract of Centella asiatica) where the madecassoside fraction was only 8% and asiaticoside was 32%. For a brand building a barrier-repair claim, that ratio is backwards. The split between madecassoside and asiaticoside in the extract matters more than the total number.

We also run our own in-house HPLC verification on every incoming batch. In most projects we’ve run, about 1 in 5 supplier batches shows meaningful deviation from the CoA — not fraud, usually just natural variation in the plant material. But that variation translates directly into batch-to-batch inconsistency in your finished product if you’re not controlling for it at intake.

The variable most brands get wrong is assuming that a higher total triterpene percentage is always better. It’s not. At above 2% total triterpene extract in a leave-on formula, we start seeing increased sensitization potential in our RIPT panels, and the texture becomes harder to work with — the extract itself contributes a slight tackiness that consumers notice. There’s a formulation sweet spot, and it’s usually not at the top of the concentration range.

Formulation Notes for Brand Partners #

When you brief us on a Centella-based product, the first thing we need to know is your primary claim and your target market. “Calming” and “post-procedure recovery” are completely different briefs, even if both use Centella asiatica on the ingredient list.

The most common mistake we see: brands request “maximum Centella concentration” without specifying which fraction. We almost always push back on this. More total extract doesn’t mean better performance — it often means higher sensitization risk and harder-to-stabilize formulas. What we actually need from you is: (1) your hero claim and the consumer problem you’re solving, (2) your target markets for regulatory alignment, (3) your texture preference and packaging format, and (4) whether you’re open to encapsulation if the stability data requires it.

One specific example: a brand came to us wanting 3% Centella extract in a clear gel serum for EU and US markets. We ran the stability and found the formula yellowed at week 6 under 40°C conditions. We reformulated at 1.5% with a liposomal delivery system and the stability held through 12 weeks. The finished product had better active delivery and a cleaner aesthetic. The brand initially pushed back on the cost — but the alternative was a failed stability package.

Timeline: lab samples in 2–3 weeks from brief confirmation, accelerated stability over 4–8 weeks, 24-month real-time stability initiated concurrently. If you need EU CPSR documentation, add 3–4 weeks for safety assessment.

Frequently Asked Questions #

Q1: We want to call it a “Centella serum” — does it matter which extract we use?
A: It matters more than most brands expect. A non-standardized leaf extract gives you the ingredient name on the INCI list, but the bioactive content can vary by 10x between batches. If you’re making any calming or barrier-repair claim, you need a standardized extract with a declared madecassoside content — minimum 0.05% in the finished formula.

Q2: Can we say “wound healing” on the pack in the EU?
A: Short answer: no, not safely. Under the EU Cosmetics Regulation 1223/2009, “wound healing” implies a medicinal function and can trigger reclassification under pharmaceutical law. We reframe these briefs as “supports skin recovery” or “helps restore the skin barrier” — same consumer benefit, compliant positioning.

Q3: We’ve heard Centella is very stable — is that true?
A: Partially. The total extract is reasonably stable. Isolated madecassoside is not — we see measurable degradation above 45°C, and in clear gel formats without a proper antioxidant package, active content can drop below 85% by week 8 of accelerated stability. Three out of five projects we’ve run with isolated madecassoside at above 0.15% required reformulation after the first stability read.

Q4: What’s your MOQ for a Centella serum, and how long does development take?
A: MOQ is typically 500kg per SKU for standard emulsion formats, lower for pilot batches at 50kg. Development timeline from confirmed brief to stability-passed formula is 10–14 weeks including accelerated stability. If you need encapsulated delivery, add 2–3 weeks for encapsulation optimization.

Q5: Should we use the same Centella formula for our EU and Asia-Pacific lines?
A: Not always — and this is the question most brands don’t think to ask. In several Asia-Pacific markets, particularly South Korea and Japan, consumer preference for texture is different enough that we often run separate emulsion bases for the same active package. More importantly, some AP markets have specific botanical ingredient registration requirements that affect how the extract is declared. We flag this in the brief stage so you’re not reformulating after regulatory review.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.